Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabilone for Agitation in Alzheimer's Disease
NCT02351882Phase 3Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jan 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Nabilone Sequence with Placebo Sequence (2 arms). Primary endpoint: Cohen-Mansfield Agitation Inventory at 14 weeks. Started Jan 2015; status: completed.
02
Drugs
nabilone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02351882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351882.